Ozempic-Like Drugs Could Lower Sales of Junk Food
Will appetite-suppressing drugs hurt the sugar industry? Executives from Walmart warned that Ozempic and Zepbound "are impacting food sales," reports Bloomberg, "and multiple analyst surveys have showed that less-hungry customers are spending fewer dollars at grocery stores and restaurants." The drugs, which cut cravings, will result in a decline in calorie consumption in the US of 1.5% to 2.5% by 2035, with a drop of as much as 5% in the consumption of sweets such as baked goods, confectionery and soda, Morgan Stanley analysts including Pamela Kaufman said in a report last month. Morgan Stanley forecast about a 10th of the US population will be on the so-called GLP-1 medications — originally designed to treat diabetes but being used by many as a powerful weight-loss tool — by 2035... Even with tight supplies and sky-high prices limiting uptake of the medications, sales of GLP-1 drugs for both obesity and diabetes already exceeded $19 billion in 2023. The global obesity market alone could top $100 billion by the end of the decade, Goldman Sachs Group Inc. estimates, while Bloomberg Intelligence forecasts $80 billion of sales. More than 60% of US consumers taking the drugs said they had cut back on sweet treats like candy, ice cream and baked goods, and many said they had either significantly — or entirely — stopped eating those products, according to Morgan Stanley.

Read more of this story at Slashdot.